May 22, 2013

Weather

Fair

82°
Conditions at North Texas Regional Airport, TX
Save Email Print Bookmark and Share
A A
Reporter: Nicole Holt Email

Candid Discussion: Migraines

Dr. DeAnn Strobel stopped by our studios for a candid discussion on migraines. What triggers a migraine? What treatments are available for this debilitating type of headache. Is a migraine more common in men or women?

If you have questions, please email nicole.holt@kxii.com.. Dr. Strobel will answer them live on First News AM on Friday morning. Remember, all questions will remain anonymous.

For more on migraines, visit these websites:

http://www.mayoclinic.com/health/migraine-headache/DS00120
http://www.neurologychannel.com/migraine/index.shtml
http://familydoctor.org/online/famdocen/home/common/brain/disorders/127.html


Comments are posted from viewers like you and do not always reflect the views of this station.
powered by Disqus

WebMD Health News

AP Top Health Stories

  • Doctors save Ohio boy by 'printing' an airway tube

    Kaiba Gionfriddo plays with the family's dog, Bandit, outside his Youngstown, Ohio home Tuesday, May 21, 2013. Born with a birth defect that caused the boy to stop breathing every day, he can now breathe normally, with a first-of-a-kind biodegradable airway made by Michigan doctors using plastic particles and a 3-D laser printer. (AP Photo/Mark Stahl)In a medical first, doctors used plastic particles and a 3-D laser printer to create an airway splint to save the life of a baby boy who used to stop breathing nearly every day.


  • Polish man gets quick face transplant after injury

    EDS NOTE GRAPHIC CONTENT -In this picture provided by the Cancer Center and Institute of Oncology in Gliwice, Poland, a 33-year-old Polish man whose face was torn off by stone-cutting machinery is shown after undergoing a total face transplant. Doctors performed the surgery on May 15 in a 27-hour operation. In a news conference on Wednesday they said it was the first time a life-saving face transplant was carried out soon after a recipient suffered damage. There have been several other transplants in recent years but in those cases doctors had months or years to prepare. The Polish patient suffered his accident on April 23, 2013.(AP Photo/Cancer Center and Institute of Oncology in Gliwice)WARSAW, Poland (AP) — A 33-year-old Polish man received a face transplant just three weeks after being disfigured in a workplace accident, in what his doctors said Wednesday is the fastest time frame to date for such an operation. It was Poland's first face transplant.


  • Cancer Society hits 100 as US cancer rate falls

    FILE - In this Nov. 15, 1979 file photo, United States Surgeon General Dr. Julius B. Richmond, at the microphones, kicks off the third annual "Smokeout" rally sponsored by the American Cancer Society in Washington, D.C. as a part of the "Great American Smokeout Day." (AP Photo)NEW YORK (AP) — The American Cancer Society — one of the nation's best known and influential health advocacy groups — is 100 years old this week.


  • Senate committee advances drug compounding bill
    By Jessica Dye NEW YORK (Reuters) - A U.S. Senate committee on Wednesday unanimously approved legislation that would increase federal oversight for companies that compound and sell sterile drugs across state lines. The proposed legislation was introduced in response to a meningitis outbreak last fall that killed more than 50 people and sickened more than 700. The outbreak was traced to contamination found in steroid injections made by the New England Compounding Center. The bill was passed unanimously on a voice vote by the Senate Health, Education, Labor and Pension Committee. ...
  • FDA panel says Merck's sleep drug safe, effective at lower dose

    A view of the Merck & Co. campus in Linden, New JerseyBy Toni Clarke WASHINGTON (Reuters) - Merck & Co's experimental insomnia drug was safe and effective at the lower of two doses studied, a panel of medical experts said on Wednesday, increasing the chance it will be approved by the U.S. Food and Drug Administration. The advisory panel was convened to help the FDA decide whether to approve the drug, suvorexant, which would be the first in a new class of sedatives designed to help people fall asleep and stay asleep. ...